Every 10-Q that Coeptis Therapeutics Holdings Inc. (COEP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow COEP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COEP filings page.
Z Squared Inc., formerly Coeptis Therapeutics Holdings, reported unaudited results for the quarter ended March 31, 2026. The company generated sales of $113,771, up from $62,874 a year earlier, but recorded a net loss of $4,020,896 and loss per share of $0.65.
Total assets were $19,786,693, including $5,211,188 of cash and $13,159,346 of investments. Stockholders’ equity was $17,578,844, while the accumulated deficit reached $113,870,346. Operating activities used $1,758,887 of cash in the quarter.
The filing highlights a going concern uncertainty, noting that recurring losses and the large accumulated deficit raise substantial doubt about the company’s ability to continue without additional financing. After March 31, 2026, the company completed a merger and spin-out that will shift its primary business to digital asset mining.
Coeptis Therapeutics Holdings (COEP) filed its Q3 2025 report, showing the first meaningful revenue from its technology segment. Sales were $237,441 in the quarter and $500,996 year-to-date, producing Q3 gross profit of $192,286.
Costs remained heavy as the company builds its biopharma and tech platforms: Q3 operating expenses were $2.67M, leading to a loss from operations of $2.48M and a net loss of $2.90M (nine‑month net loss $10.65M). Cash improved to $4.91M at September 30, 2025, up from $0.53M at year‑end, driven by financing inflows of $11.29M year‑to‑date (including a Q3 private placement of 436,467 shares for $5.0M). Operating cash use was $6.92M year‑to‑date.
The company reported $1.46M in customer deposits and completed the exclusive GEAR cell therapy license, paying $400,000 in 2025 with future milestones. Equity activity was significant: common shares outstanding rose to 5,157,611 at September 30, 2025, and 5,340,111 as of November 11, 2025. Management disclosed that recurring losses and an accumulated deficit of $108.38M raise substantial doubt about continuing as a going concern, with plans to seek additional financing.
Coeptis Therapeutics Holdings, Inc. reported interim financials showing operating losses and financing activity. For the six months ended June 30, 2025, the Company recorded a net loss of $7,755,527 and management states these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company completed a retrospective 20-for-1 reverse stock split, with 4,166,713 shares issued and outstanding at June 30, 2025 (4,820,317 noted as outstanding as of August 13, 2025). Debt and capital transactions were active: a $1,304,758 convertible note was converted by Yorkville (including $52,505 of accrued interest) into 233,500 shares at an average $5.81 conversion price, and the Company recognized a $906,429 gain on change in fair value of a derivative liability during the six months. The Company shows various convertible notes, a $150,000 SBA EIDL balance, warrant liabilities, investments recorded for transferred subscription receivables, and $1,344,750 of unamortized stock-based compensation for options. Management plans to raise additional equity or debt to fund operations, but states no assurance of success.